{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:31:01Z","timestamp":1795102261397,"version":"4.10.3"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To assess the effect of once-daily relugolix combination therapy (relugolix-CT: relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) compared with placebo on moderate-to-severe pain in women with uterine leiomyomas and heavy menstrual bleeding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>Two replicate, multinational, double-blind, 24-week, randomized, phase 3 studies (LIBERTY 1 and 2) were conducted in premenopausal women with uterine leiomyoma\u2013associated heavy menstrual bleeding (80 mL or greater per cycle for two cycles or 160 mL or greater during one cycle). A predefined secondary objective was to determine the effect of relugolix-CT on moderate-to-severe uterine leiomyoma\u2013associated pain in the pain subpopulation (women with maximum pain scores of 4 or higher on the 0\u201310 numerical rating scale at baseline, with pain score reporting compliance of 80% (ie, 28 days or more over the last 35 days of treatment). This key secondary endpoint was defined as the proportion of women achieving minimal-to-no uterine leiomyoma\u2013associated pain (maximum numerical rating scale score 1 or lower) at week 24; menstrual and nonmenstrual pain were evaluated in prespecified secondary analyses. Treatment comparisons were performed in the pooled LIBERTY 1 and 2 pain subpopulation using the Cochran-Mantel-Haenszel test stratified by baseline menstrual blood loss volume.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Across both trials, 509 women were randomized to relugolix-CT or placebo (April 2017\u2013December 2018). Of these, 277 (54.4%) met pain subpopulation requirements. With relugolix-CT, 45.2% (95% CI 36.4\u201354.3) of women achieved minimal-to-no pain compared with 13.9% (95% CI 8.8\u201320.5) with placebo (nominal <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001). The proportions of women with minimal-to-no pain during menstrual days and during nonmenstrual days were significantly higher with relugolix-CT (65.0% [95% CI 55.6\u201373.5] and 44.6% [95% CI 32.3\u201357.5], respectively) compared with placebo (19.3% [95% CI 13.2\u201326.7], nominal <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001, and 21.6% [95% CI 12.9\u201332.7], nominal <jats:italic toggle=\"yes\">P<\/jats:italic>=.004, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma\u2013associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma\u2013associated pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>FUNDING SOURCE:<\/jats:title>\n            <jats:p>Myovant Sciences GmbH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004787","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:05:56Z","timestamp":1654167956000},"page":"1070-1081","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Relugolix Combination Therapy for Uterine Leiomyoma\u2013Associated Pain in the LIBERTY Randomized Trials"],"prefix":"10.1097","volume":"139","author":[{"given":"Elizabeth A.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea S.","family":"Lukes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Venturella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Camilo","family":"Arjona Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Hunsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Wagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al-Hendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","article-title":"Clinical practice. Uterine fibroids","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.maturitas.2014.06.002","article-title":"EMAS position statement: management of uterine fibroids","volume":"79","author":"Perez-Lopez","year":"2014","journal-title":"Maturitas"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/GRF.0000000000000164","article-title":"Epidemiology of uterine fibroids: from menarche to menopause","volume":"59","author":"Wise","year":"2016","journal-title":"Clin Obstet Gynecol"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/AOG.0b013e31820780e3","article-title":"Uterine leiomyomas: individualizing the approach to a heterogeneous condition","volume":"117","author":"Laughlin","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6874-12-6","article-title":"Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women","volume":"12","author":"Zimmermann","year":"2012","journal-title":"BMC Womens Health"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejogrb.2016.02.026","article-title":"Myoma-associated pain frequency and intensity: a retrospective evaluation of 1548 myoma patients","volume":"199","author":"David","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/IJWH.S133212","article-title":"Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis","volume":"9","author":"Fuldeore","year":"2017","journal-title":"Int J Womens Health"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00404-016-4239-y","article-title":"Symptoms of uterine myomas: data of an epidemiological study in Germany","volume":"295","author":"Foth","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejogrb.2018.05.026","article-title":"Epidemiology of uterine myomas and clinical practice in Spain: an observational study","volume":"226","author":"Monleon","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/humupd\/dmh019","article-title":"Sex steroidal regulation of uterine leiomyoma growth and apoptosis","volume":"10","author":"Maruo","year":"2004","journal-title":"Hum Reprod Update"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.AOG.0000165827.66541.dd","article-title":"Prospective data collection of a new procedure by a specialty society: the FIBROID registry","volume":"106","author":"Myers","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/00016346609158455","article-title":"Menstrual blood loss--a population study. Variation at different ages and attempts to define normality","volume":"45","author":"Hallberg","year":"1966","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijgo.12666","article-title":"The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions","volume":"143","author":"Munro","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in Black and White women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"017","DOI":"10.23937\/2474-1353\/1510017","article-title":"Menstrual pain assessment: comparing verbal rating scale (VRS) with numerical rating scales (NRS) as pain measurement tools","volume":"2","author":"Ameade","year":"2016","journal-title":"Int J Womens Health Wellness"},{"key":"R17-20250423","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"R18-20250423","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1080\/03007995.2017.1372107","article-title":"Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey","volume":"33","author":"Soliman","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"R20-20250423","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12905-021-01475-2","article-title":"Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial","volume":"21","author":"Hoshiai","year":"2021","journal-title":"BMC Womens Health"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial","volume":"133","author":"Osuga","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R23-20250423","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0002-9378(90)90667-V","article-title":"Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis","volume":"163","author":"Friedman","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"R24-20250423","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/11537290-000000000-00000","article-title":"Development of an electronic daily uterine fibroid symptom diary","volume":"4","author":"Deal","year":"2011","journal-title":"Patient"},{"key":"R26-20250423","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-0037-1607264","article-title":"Uterine fibroids: burden and unmet medical need","volume":"35","author":"Al-Hendy","year":"2017","journal-title":"Semin Reprod Med"},{"key":"R27-20250423","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bpobgyn.2017.10.001","article-title":"Alternatives to hysterectomy: the burden of fibroids and the quality of life","volume":"46","author":"Fortin","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"}],"updated-by":[{"DOI":"10.1097\/aog.0000000000004858","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000}}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:03:54Z","timestamp":1745435034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004787","relation":{"correction":[{"id-type":"doi","id":"10.1097\/AOG.0000000000004858","asserted-by":"object"}]},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"2021-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}